Risk factors
Anaptysbio (ANAB) risk factors
Item 1A of every Anaptysbio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2024 10-K risk factors56 risks
AnaptysBio faces typical clinical-stage biotech risks dominated by trial outcomes for rosnilimab, ANB033, and ANB101, heavy reliance on GSK collaboration, and the need for significant future capital.
Filed Feb 27, 2025